MedTrace Logo

PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

NCT03791905 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2021-03-23

No results posted yet for this study

Summary

Since multiple studies have demonstrated that PET can identify responders and non-responders to induction chemotherapy, using FDG-PET imaging to guide treatment decisions has prompted interest in clinical practice. The aim of this study was to evaluate whether changing chemotherapy regimen during radiation based on PET response to induction chemotherapy can improve clinical complete response (cCR) in patients with unresectable esophageal squamous cell carcinoma (ESCC).

Conditions

Interventions

DRUG

Paclitaxel

chemotherapy drug

DRUG

Cisplatin

chemotherapy drug

DRUG

Oxaliplatin

chemotherapy drug

DRUG

5-FU

chemotherapy drug

DRUG

Leucovorin

chemotherapy drug

RADIATION

Intensity-modulated radiotherapy

radiotherapy technique

DEVICE

PET

Using PET to evaluate response to induction chemotherapy

Sponsors & Collaborators

  • Mian XI

    lead OTHER

Principal Investigators

  • Mian XI, MD · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-15
Primary Completion
2021-07-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03791905 on ClinicalTrials.gov